Arbutus Biopharma (NASDAQ:ABUS) Downgraded to “Sell” Rating by StockNews.com
StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Hone Health on MSN23h
The red flag for heart disease in women you probably haven't heard about
Iryna Inshyna // Shutterstock New insights on heart disease and menopause. A s if hot flashes, mood swings, uncomfortable sex ...
Barchart on MSN22h
Benitec - Another Biopharma Rocket
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to the biopharmceutical company Benitec Biopharma (BNTC) . I found the stock by ...
High Growth Tech in Europe Featuring Three Promising Stocks
Amidst a backdrop of uncertainty surrounding U.S. trade policy and economic fluctuations, the European market has been experiencing mixed results, with the pan-European STOXX Europe 600 Index ending ...